What are GLP-1 medications and how do they work for weight loss?

GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medications that mimic a natural gut hormone to suppress appetite, slow gastric emptying, and regulate blood sugar, leading to significant calorie reduction and weight loss. They were originally developed for type 2 diabetes but have since been FDA-approved for chronic weight management.

How much weight can you realistically lose on GLP-1 medications?

Clinical trials show that GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) can produce an average weight loss of 15–22% of total body weight over 68–72 weeks when combined with diet and exercise. Individual results vary based on dosage, adherence, and lifestyle factors.

What are the most common side effects of GLP-1 weight loss drugs?

The most frequently reported side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which are typically most pronounced when starting the medication or increasing the dose. These symptoms usually subside as the body adjusts over several weeks.

Do you need a prescription to get GLP-1 medications, and are they covered by insurance?

Yes, all FDA-approved GLP-1 weight loss medications require a prescription from a licensed healthcare provider. Insurance coverage varies widely — many plans cover them for diabetes but not always for weight loss, though coverage has been expanding in 2025–2026 as clinical evidence grows.

Will you regain weight if you stop taking GLP-1 medications?

Research indicates that most people regain a significant portion of lost weight — often two-thirds or more — within one year of stopping GLP-1 therapy, as the underlying appetite-regulating mechanisms return to baseline. This has led many clinicians to view GLP-1 treatment as a long-term or chronic condition management strategy rather than a short-term intervention.

Novo Nordisk / Wikipedia

Compare

Top 10 GLP-1 Weight Loss Medications Transforming Health in 2026

In 2026, GLP-1 weight loss medications are revolutionizing obesity care, with semaglutide (Wegovy, Ozempic) achieving 15% average weight loss and the breakthrough once-daily oral orforglipron reaching up to 25%. These FDA-approved agonists mimic a natural hormone, reducing appetite, improving blood sugar, and even lowering cardiovascular risk. Unlike prior options, they target root metabolic dysfunction. Here are the top 10 drugs transforming health this year—game-changers that are redefining treatment beyond the scale.

Community-RankedUpdated Sep 7, 2026

Something seismic is happening in medicine. For decades, obesity was treated as a willpower problem, addressed with vague lifestyle advice and drugs that produced modest results and worrying side effects. Then came glucagon-like peptide-1 receptor agonists — GLP-1s — and the entire field tilted on its axis. What began as a class of diabetes medications has become the most consequential pharmaceutical development of the 21st century, delivering weight losses that were once achievable only through bariatric surgery, and now demonstrating the power to reduce heart attacks, slow kidney decline, reverse fatty liver disease, and eliminate obstructive sleep apnea. In 2026, the landscape has never been richer or more competitive. Novo Nordisk's Wegovy — already the bestselling weight-loss drug in history — gained a pill form approved by the FDA in December 2025, democratizing access for patients who fear needles. Eli Lilly's Zepbound, a dual GIP and GLP-1 agonist, has become the most prescribed weight management medication in the United States and was cleared for obstructive sleep apnea, the first drug ever approved for that condition. The even newer oral non-peptide option Foundayo (orforglipron), also from Lilly, can be taken at any time of day without food restrictions — a meaningful daily-life advantage — and launched commercially in April 2026 at a self-pay price of just $149 per month. Beyond the approved drugs, the pipeline is extraordinary. Retatrutide, Lilly's triple-agonist compound targeting GLP-1, GIP, and glucagon receptors simultaneously, delivered 30.3% average body weight reduction in its Phase 3 TRIUMPH-1 trial announced in May 2026 — the highest weight-loss signal ever recorded in a randomized controlled trial. CagriSema, Novo Nordisk's fixed-dose combination of semaglutide and the amylin analogue cagrilintide, has an FDA application under active review after producing 23% average weight loss in Phase 3. Amgen's MariTide — a once-monthly injectable bispecific that agonizes GLP-1 receptors and antagonizes GIP receptors — is in Phase 3 with up to 20% weight loss already demonstrated at Phase 2, and offers a once-monthly dosing regimen that could transform adherence. This list ranks the ten most significant GLP-1 and GLP-1-adjacent weight loss drugs of 2026 across six dimensions: raw weight-loss efficacy, FDA approval status, route of administration convenience, side-effect profile, cost and accessibility, and additional health benefits beyond the scale. Whether you are a patient navigating options with your physician, a clinician tracking the evidence, or a health-curious reader trying to understand what all the headlines mean, this ranking will give you the clearest, most data-grounded view of where the science stands right now. One caveat bears repeating: none of these medications is a magic pill. The clinical trials that produced these stunning numbers were conducted alongside reduced-calorie diets and increased physical activity. The drugs work by suppressing appetite, slowing gastric emptying, modulating reward circuits in the brain, and in some cases directly improving insulin sensitivity and energy expenditure. They do not eliminate the need for healthy behaviors. What they do — and this is the revolution — is make those behaviors dramatically easier to sustain.

165 viewsJul 12, 2026 Updated Sep 7, 2026

Be the first

Compare by Dimension

Average % body weight reduction in pivotal trials

Rank	Item	Score	Notes
#1	Retatrutide (Triple Agonist, Investigational)	10.0	Retatrutide achieves 30.3% in TRIUMPH-1 Phase 3 — unprecedented efficacy, ranks above all approved drugs on this dimension alone
#2	Zepbound (Tirzepatide)	9.0	Zepbound leads all approved drugs with 20.9% average weight loss at 15 mg in SURMOUNT-1 — highest of any FDA-approved medication
#3	CagriSema (Cagrilintide + Semaglutide)	8.0	CagriSema delivers 22.7% in REDEFINE 1 Phase 3 (adherent population) — second only to retatrutide among pipeline drugs
#4	MariTide (Maridebart Cafraglutide, Investigational)	8.0	MariTide shows up to 20% weight loss in Phase 2 non-diabetic participants — competitive with Zepbound but Phase 3 data pending
#5	Wegovy (Semaglutide Injection 2.4 mg)	7.0	Wegovy injection averages 14.9-16.6% in STEP trials — strong but below Zepbound's dual-agonist ceiling
#6	Wegovy Pill / Oral Semaglutide 25 mg (Weight Management)	7.0	Oral Wegovy 25 mg averages 16.6% in OASIS 4 among adherent participants — matches injectable Wegovy in ideal conditions
#7	Foundayo (Orforglipron)	5.0	Foundayo achieves 12.4% average weight loss at highest dose — effective but lower than all other semaglutide and tirzepatide formulations
#8	Ozempic (Semaglutide Injection, Diabetes + Kidney)	4.0	Ozempic produces 5-10% weight loss at 1-2 mg doses — moderate and below its 2.4 mg Wegovy formulation
#9	Saxenda (Liraglutide 3 mg)	3.0	Saxenda delivers 8-10% average weight loss in SCALE trials — meaningful but the lowest efficacy among fully approved options on this list
#10	Rybelsus (Oral Semaglutide 14 mg, Diabetes)	2.0	Rybelsus produces only 4-5 kg average weight loss at 14 mg in PIONEER trials — primarily a glycemic drug, not an obesity drug

Current Rankings

0
#1
Zepbound (Tirzepatide)
Zepbound (tirzepatide) delivers the highest FDA-approved weight-loss efficacy ever recorded, with patients losing an average of 20.9% of body weight — about 48 pounds — at the 15 mg dose in the SURMOUNT-1 trial. Data from the 72-week SURMOUNT-2 trial in patients with type 2 diabetes showed 12-15% weight loss, significantly exceeding any comparator. Approved in December 2024, it is also the only prescription medication to treat moderate-to-severe obstructive sleep apnea in adults with obesity, reducing apnea events by 25-29 per hour versus placebo. A 2026 monthly KwikPen delivers four doses via a single device, and pricing starts at $299 per month through LillyDirect, with savings cards lowering costs to $25 for eligible patients.
More info →
Details →
0
#2
Wegovy (Semaglutide Injection 2.4 mg)
Wegovy (semaglutide 2.4 mg) is the only weight-loss drug with a proven cardiovascular benefit, reducing major adverse cardiac events by 20% in the SELECT trial of 17,604 non-diabetic adults. However, Wegovy's landmark cardiovascular risk-reduction indication, approved in March 2024, provides unmatched heart protection. Weekly doses escalate over 16-20 weeks to minimize side effects, and monthly list price is approximately $1,349, with savings programs reducing costs to $25 per month for eligible patients.
More info →
Details →
0
#3
Retatrutide (Triple Agonist, Investigational)
Retatrutide, Eli Lilly's investigational triple GLP-1/GIP/glucagon receptor agonist, achieved a 30.3% average weight loss in the TRIUMPH-1 Phase 3 trial — the highest ever recorded in a randomized obesity trial. At 12 mg weekly over 96 weeks, participants lost approximately 70-71 pounds, with additional benefits including a 75.8% reduction in osteoarthritis pain and a 72% reversal rate of prediabetes. An NDA filing is expected in late 2026, with approval anticipated in 2027; no list price or commercial name is yet available.
More info →
Details →
0
#4
CagriSema (Cagrilintide + Semaglutide)
Among completers, 91.9% lost at least 5% of body weight versus 31.5% with placebo, with one-third losing 25% or more. An NDA was submitted to the FDA on December 18, 2025, positioning it as the most advanced next-generation obesity therapy. Approval is expected by late 2026 or early 2027; no list price or commercial brand is yet available.
More info →
Details →
0
#5
Wegovy Pill / Oral Semaglutide 25 mg (Weight Management)
The oral Wegovy pill (oral semaglutide 25 mg) is the first FDA-approved oral GLP-1 specifically for weight management, eliminating the need for self-injection while matching injectable Wegovy's efficacy. Approved on December 22, 2025, and launched in January 2026, the OASIS 4 Phase 3 trial showed adherent participants lost an average of 16.6% body weight, with one-third achieving at least 20% weight loss compared to under 3% for placebo. Its cardiovascular risk-reduction indication adds clinical depth. However, the strict fasting requirement—no food for 6 hours, only 4 oz of water, and a 30-minute post-ingestion wait—creates adherence challenges. This dosing protocol is stricter than Foundayo (orforglipron), which can be taken at any time without food restrictions. At a list price of $499 per month with savings programs, it is a potent but logistically demanding option.
More info →
Details →
0
#6
Foundayo (Orforglipron)
Foundayo (orforglipron) by Eli Lilly is the first FDA-approved non-peptide small-molecule oral GLP-1, approved on April 1, 2026, offering flexible intake with or without food—a critical real-world advantage over oral semaglutide (Wegovy oral), which requires strict fasting. The Phase 3 ATTAIN trial demonstrated a 12.4% average weight loss at 36 mg daily over 72 weeks, with 60% of participants achieving at least 10% reduction. While 12.4% is lower than oral semaglutide's 16.6%, the no-food-restriction dosing likely improves long-term adherence. A standout feature is pricing: $149 per month for self-pay patients, which is dramatically lower than every other GLP-1, with commercially insured patients paying as low as $25 via savings card. Cardiovascular outcomes trials are ongoing, and this affordability could expand GLP-1 access widely.
More info →
Details →
0
#7
Ozempic (Semaglutide Injection, Diabetes + Kidney)
Ozempic (semaglutide up to 2 mg weekly) holds the most expansive FDA indications of any GLP-1, including glycemic control in type 2 diabetes, reduction of major adverse cardiovascular events, and, as of January 28, 2025, reduction of worsening kidney disease and cardiovascular death in type 2 diabetes patients with CKD. The Phase 3b FLOW trial demonstrated a 24% relative risk reduction in a composite of kidney disease worsening, end-stage kidney disease, and cardiovascular death, plus a 29% relative risk reduction in CV death—making it the only GLP-1 RA with a kidney protection indication. While not formally approved for weight management, it induces 5-10% weight reduction at 1-2 mg doses. At a monthly list price of $900-$1,000 without insurance, it provides a lower-cost entry into the GLP-1 class for millions compared to Wegovy, with better diabetes coverage.
More info →
Details →
0
#8
MariTide (Maridebart Cafraglutide, Investigational)
MariTide (maridebart cafraglutide) by Amgen is a novel investigational antibody-peptide conjugate that uniquely agonizes GLP-1 while antagonizing GIP—the inverse mechanism of tirzepatide, offering a distinct metabolic pathway. Phase 2 data in the New England Journal of Medicine showed approximately 20% weight loss in non-diabetic adults after 52 weeks and about 17% in those with type 2 diabetes, with HbA1c reductions of up to 1.6 percentage points. Crucially, MariTide demonstrated sustained weight loss for up to 52 weeks after treatment stopped, a durability advantage over peptide-based GLP-1s like Ozempic (semaglutide injection), whose effects wane quickly. Its most disruptive feature is once-monthly dosing, potentially once-quarterly, versus weekly injections for all current GLP-1s. However, Phase 2 results fell short of analyst expectations, and Phase 3 trials are ongoing through 2026-2027.
More info →
Details →
0
#9
Rybelsus (Oral Semaglutide 14 mg, Diabetes)
Rybelsus (Oral Semaglutide 14 mg) stands alone as the only oral GLP-1 approved for both glycemic control and cardiovascular risk reduction in type 2 diabetes, a dual indication that expands its therapeutic reach since its September 2019 debut as the first oral GLP-1. By leveraging Novo Nordisk's SNAC absorption enhancer, it overcomes gastric degradation to deliver systemic absorption, and the SOUL trial (n=9,650) confirmed a 14% relative reduction in major adverse cardiovascular events versus placebo over 4 years, earning FDA approval for cardiovascular risk reduction in October 2025. Rybelsus requires strict fasting: an empty stomach, no more than 120 mL of water, and 30 minutes without food or medications. For T2D patients with established cardiovascular disease, Rybelsus remains the definitive oral option, even as oral Wegovy (25 mg) enters the market.
More info →
Details →
0
#10
Saxenda (Liraglutide 3 mg)
Saxenda (liraglutide 3 mg) pioneered chronic weight management as the first GLP-1 approved for that indication in December 2014, achieving an average 8-10% body weight loss in the SCALE trials over 56 weeks—outperforming orlistat's 3-5% average by 167%. The SCALE Obesity and Prediabetes trial reported 5.8 kg weight loss versus 1.6 kg with placebo. Once-daily injections leverage an 18-24 hour half-life, and Saxenda uniquely holds approval for adolescents aged 12-17. The key development in 2025-2026 is FDA approval of generic liraglutide, reducing monthly costs to $230-$500 compared to Saxenda's $1,349 list price; Teva's program can drop it to $20 per prescription for commercially insured patients.
More info →
Details →

Current Rankings

Share this list

165 views

Get ranking updates

Get the weekly health rundown

The most-voted lists across every category — curated weekly. Join the early readers.

The most-voted lists across every category
Exclusive early-access to new categories
Reader picks vs editorial picks compared

No spam. One email per week. Unsubscribe anytime.

GLP-1 Weight Loss Medications: Frequently Asked Questions

## How much weight can GLP-1 medications help me lose? FDA-approved agents like Wegovy and Zepbound typically produce 10-15% body-weight reduction over 60-72 weeks when combined with lifestyle counseling.

## Are GLP-1 medications safe for long-term use? Semaglutide and tirzepatide are approved for chronic management; ongoing cardiovascular and renal monitoring is recommended.

## Will insurance cover these drugs? Coverage varies by payer and indication; manufacturers offer savings programs for commercially insured patients.

## What side effects should I expect? Common gastrointestinal effects (nausea, constipation, diarrhea) usually diminish within the first 12 weeks.

## Do lifestyle changes still matter? Yes — diet and physical activity remain foundational; medications amplify but do not replace behavioral intervention.

Frequently Asked Questions

- How effective are these medications?

GLP‑1 drugs produce 5‑15% weight loss on average, with some patients losing up to 25%.

- What are the main side effects?

Common side effects include nausea, vomiting, diarrhea, and constipation, usually mild and temporary.

- How are they administered?

Most are weekly injections, but oral semaglutide (Wegovy pill) and oral orforglipron are taken daily.

- Are they approved for everyone?

Eligibility depends on BMI and health conditions; a doctor’s prescription is required.

- Do they lower cardiovascular risk?

Studies show reduced heart events and stroke risk in people with obesity and related conditions.

GLP-1 Weight Loss Medications: Frequently Asked Questions

## What is a GLP-1 medication? GLP-1 (glucagon-like peptide-1) medications are drugs that mimic a natural gut hormone to reduce appetite, slow digestion, and improve blood sugar control.

## How much weight can you lose on GLP-1 drugs? Results vary by drug and individual. In clinical trials, Wegovy (semaglutide 2.4 mg) produced an average of about 15% body-weight loss, while orforglipron has reported up to 25% in trials.

## Are oral GLP-1 medications as effective as injections? The oral Wegovy pill (semaglutide 25 mg) and orforglipron are designed to deliver similar efficacy to injectables. Your doctor can advise which form is appropriate for you.

## What are common side effects? The most reported side effects are nausea, vomiting, diarrhea, and constipation, especially during dose escalation. Most symptoms lessen over time.

## Who should not take GLP-1 medications? People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 should avoid GLP-1 agonists. Always consult a qualified clinician before starting any medication on this list.

Have a question we missed? Vote on the list and share your experience in the comments.